Down-regulated miR-28-5p in human hepatocellular carcinoma correlated with tumor proliferation and migration by targeting insulin-like growth factor-1 (IGF-1)

Molecular and Cellular Biochemistry

Volumn 408, Issue 1-2, 2015, Pages 283-293

  Shi, Xiaomin ^a   Teng, Fei ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Hepatocellular carcinoma; IGF1; miRNA 28 5p; PI3K AKT

Indexed keywords

MESSENGER RNA; MICRORNA; MICRORNA 28 5P; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; SOMATOMEDIN C; UNCLASSIFIED DRUG; 3' UNTRANSLATED REGION; IGF1 PROTEIN, HUMAN; MIRN28 MICRORNA, HUMAN;

3' UNTRANSLATED REGION; ADULT; APOPTOSIS; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HEPATOMA CELL; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; LIVER CELL CARCINOMA; MALE; METASTASIS; MIDDLE AGED; PROTEIN EXPRESSION; RNA TRANSLATION; TUMOR GROWTH; WESTERN BLOTTING; CELL MOTION; CELL PROLIFERATION; DOWN REGULATION; GENE EXPRESSION REGULATION; GENETICS; HEPG2 CELL LINE; LIVER TUMOR; PATHOLOGY; PROGNOSIS; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

3' UNTRANSLATED REGIONS; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; DOWN-REGULATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HEP G2 CELLS; HUMANS; INSULIN-LIKE GROWTH FACTOR I; LIVER NEOPLASMS; MALE; MICRORNAS; PROGNOSIS; SIGNAL TRANSDUCTION;

EID: 84941957599     PISSN: 03008177     EISSN: 15734919     Source Type: Journal    
DOI: 10.1007/s11010-015-2506-z     Document Type: Article

References (33)

1. Qasim W, Brunetto M, Gehring A, Xue SA, Schurich A, Khakpoor A et al (2014) Immunotherapy of HCC metastases with autologous T cell receptor redirected T cells targeting HBsAg in a liver transplant patient. J Hepatol. doi:10.1016/j.jhep.2014.10.001
2. Ringelhan M, Protzer U, O’Connor T, Heikenwalder M (2014) The direct and indirect role of HBV in liver cancer: prospective markers for HCC-screening and potential therapeutic targets. J Pathol. doi:10.1002/path.4434
3. Palmer DH, Hussain SA, Smith AJ, Hargreaves S, Ma YT, Hull D et al (2013) Sorafenib for advanced hepatocellular carcinoma (HCC): impact of rationing in the United Kingdom. Br J Cancer 109(4):888–890. doi:10.1038/bjc.2013.410
4. Printz C (2009) Clinical trials of note. Sorafenib as adjuvant treatment in the prevention of disease recurrence in patients with hepatocellular carcinoma (HCC) (STORM). Cancer 115(20):4646. doi:10.1002/cncr.24673
5. Mori M, Triboulet R, Mohseni M, Schlegelmilch K, Shrestha K, Camargo FD et al (2014) Hippo signaling regulates microprocessor and links cell-density-dependent miRNA biogenesis to cancer. Cell 156(5):893–906. doi:10.1016/j.cell.2013.12.043
6. Ruvkun G (2006) Clarifications on miRNA and cancer. Science 311(5757):36–37. doi:10.1126/science.311.5757.36d
7. Li W, Liu M, Feng Y, Xu YF, Huang YF, Che JP et al (2014) Downregulated miR-646 in clear cell renal carcinoma correlated with tumour metastasis by targeting the nin one binding protein (NOB1). Br J Cancer 111(6):1188–1200. doi:10.1038/bjc.2014.382
8. Utsunomiya T, Ishikawa D, Asanoma M, Yamada S, Iwahashi S, Kanamoto M et al (2014) Specific miRNA expression profiles of non-tumor liver tissue predict a risk for recurrence of hepatocellular carcinoma. Hepatol Res 44(6):631–638. doi:10.1111/hepr.12164
9. Chen W, Cai F, Zhang B, Barekati Z, Zhong XY (2013) The level of circulating miRNA-10b and miRNA-373 in detecting lymph node metastasis of breast cancer: potential biomarkers. Tumour Biol 34(1):455–462. doi:10.1007/s13277-012-0570-5
10. Wagner S, Ngezahayo A, Murua Escobar H, Nolte I (2014) Role of miRNA let-7 and its major targets in prostate cancer. BioMed Res Int 2014:376326. doi:10.1155/2014/376326
11. Heron-Milhavet L, Karas M, Goldsmith CM, Baum BJ, LeRoith D (2001) Insulin-like growth factor-I (IGF-I) receptor activation rescues UV-damaged cells through a p38 signaling pathway. Potential role of the IGF-I receptor in DNA repair. J Biol Chem 276(21):18185–18192. doi:10.1074/jbc.M011490200
12. Bodzin AS, Wei Z, Hurtt R, Gu T, Doria C (2012) Gefitinib resistance in HCC mahlavu cells: upregulation of CD133 expression, activation of IGF-1R signaling pathway, and enhancement of IGF-1R nuclear translocation. J Cell Physiol 227(7):2947–2952. doi:10.1002/jcp.23041
13. Locatelli D, Terao M, Fratelli M, Zanetti A, Kurosaki M, Lupi M et al (2012) Human axonal survival of motor neuron (a-SMN) protein stimulates axon growth, cell motility, C-C motif ligand 2 (CCL2), and insulin-like growth factor-1 (IGF1) production. J Biol Chem 287(31):25782–25794. doi:10.1074/jbc.M112.362830
14. Zhou Y, Capuco AV, Jiang H (2008) Involvement of connective tissue growth factor (CTGF) in insulin-like growth factor-I (IGF1) stimulation of proliferation of a bovine mammary epithelial cell line. Domest Anim Endocrinol 35(2):180–189. doi:10.1016/j.domaniend.2008.05.003
15. Koti M, Gooding RJ, Nuin P, Haslehurst A, Crane C, Weberpals J et al (2013) Identification of the IGF1/PI3K/NF kappaB/ERK gene signalling networks associated with chemotherapy resistance and treatment response in high-grade serous epithelial ovarian cancer. BMC Cancer 13:549. doi:10.1186/1471-2407-13-549
16. Matta M, Bongard V, Grunenwald S, Maiza JC, Bennet A, Caron P (2011) Clinical and metabolic characteristics of acromegalic patients with high IGF1/normal GH levels during somatostatin analog treatment. Eur J Endocrinol 164(6):885–889. doi:10.1530/EJE-11-0098
17. Subramanian A, Sharma AK, Banerjee D, Jiang WG, Mokbel K (2007) Evidence for a tumour suppressive function of IGF1-binding proteins in human breast cancer. Anticancer Res 27(5B):3513–3518
18. Xu Q, Jiang Y, Yin Y, Li Q, He J, Jing Y et al (2013) A regulatory circuit of miR-148a/152 and DNMT1 in modulating cell transformation and tumor angiogenesis through IGF-IR and IRS1. J Mol Cell Biol 5(1):3–13. doi:10.1093/jmcb/mjs049
19. Noh JH, Chang YG, Kim MG, Jung KH, Kim JK, Bae HJ et al (2013) MiR-145 functions as a tumor suppressor by directly targeting histone deacetylase 2 in liver cancer. Cancer Lett 335(2):455–462. doi:10.1016/j.canlet.2013.03.003
20. Pagliuca A, Valvo C, Fabrizi E, di Martino S, Biffoni M, Runci D et al (2013) Analysis of the combined action of miR-143 and miR-145 on oncogenic pathways in colorectal cancer cells reveals a coordinate program of gene repression. Oncogene 32(40):4806–4813. doi:10.1038/onc.2012.495
21. Almeida MI, Nicoloso MS, Zeng L, Ivan C, Spizzo R, Gafa R et al (2012) Strand-specific miR-28-5p and miR-28-3p have distinct effects in colorectal cancer cells. Gastroenterology 142(4):886–896 e9. doi:10.1053/j.gastro.2011.12.047
22. Bolos D, Finn RS (2014) Systemic therapy in HCC: lessons from brivanib. J Hepatol 61(4):947–950. doi:10.1016/j.jhep.2014.06.019
23. Huang X, Jia Z (2013) Construction of HCC-targeting artificial miRNAs using natural miRNA precursors. Exp Ther Med 6(1):209–215. doi:10.3892/etm.2013.1111
24. Goto M, Iwase A, Harata T, Takigawa S, Suzuki K, Manabe S et al (2009) IGF1-induced AKT phosphorylation and cell proliferation are suppressed with the increase in PTEN during luteinization in human granulosa cells. Reproduction 137(5):835–842. doi:10.1530/REP-08-0315
25. Montenegro LR, Leal AC, Coutinho DC, Valassi HP, Nishi MY, Arnhold IJ et al (2012) Post-receptor IGF1 insensitivity restricted to the MAPK pathway in a Silver-Russell syndrome patient with hypomethylation at the imprinting control region on chromosome 11. Eur J Endocrinol 166(3):543–550. doi:10.1530/EJE-11-0964
26. Yang X, Cheng Y, Li P, Tao J, Deng X, Zhang X et al (2014) A lentiviral sponge for miRNA-21 diminishes aerobic glycolysis in bladder cancer T24 cells via the PTEN/PI3K/AKT/mTOR axis. Tumour Biol. doi:10.1007/s13277-014-2617-2
27. Rao E, Jiang C, Ji M, Huang X, Iqbal J, Lenz G et al (2012) The miRNA-17 approximately 92 cluster mediates chemoresistance and enhances tumor growth in mantle cell lymphoma via PI3K/AKT pathway activation. Leukemia 26(5):1064–1072. doi:10.1038/leu.2011.305
28. Endogenous H, Breast Cancer Collaborative G, Key TJ, Appleby PN, Reeves GK, Roddam AW (2010) Insulin-like growth factor 1 (IGF1), IGF binding protein 3 (IGFBP3), and breast cancer risk: pooled individual data analysis of 17 prospective studies. Lancet Oncol 11(6):530–542. doi:10.1016/S1470-2045(10)70095-4
29. Jernstrom H, Sandberg T, Bageman E, Borg A, Olsson H (2005) Insulin-like growth factor-1 (IGF1) genotype predicts breast volume after pregnancy and hormonal contraception and is associated with circulating IGF-1 levels: implications for risk of early-onset breast cancer in young women from hereditary breast cancer families. Br J Cancer 92(5):857–866. doi:10.1038/sj.bjc.6602389
30. Rosenzweig SA, Atreya HS (2010) Defining the pathway to insulin-like growth factor system targeting in cancer. Biochem Pharmacol 80(8):1115–1124. doi:10.1016/j.bcp.2010.06.013
31. Galer CE, Corey CL, Wang Z, Younes MN, Gomez-Rivera F, Jasser SA et al (2011) Dual inhibition of epidermal growth factor receptor and insulin-like growth factor receptor I: reduction of angiogenesis and tumor growth in cutaneous squamous cell carcinoma. Head Neck 33(2):189–198. doi:10.1002/hed.21419
32. Schmitz S, Kaminsky-Forrett MC, Henry S, Zanetta S, Geoffrois L, Bompas E et al (2012) Phase II study of figitumumab in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck: clinical activity and molecular response (GORTEC 2008-02). Ann Oncol 23(8):2153–2161. doi:10.1093/annonc/mdr574
33. Chi KN, Gleave ME, Fazli L, Goldenberg SL, So A, Kollmannsberger C et al (2012) A phase II pharmacodynamic study of preoperative figitumumab in patients with localized prostate cancer. Clin Cancer Res 18(12):3407–3413. doi:10.1158/1078-0432.CCR-12-0482